Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles
Source abstract
Abstract
Poly(lactic acid-lactic acid) (PLGA) has demonstrated significant application potential in tumor-targeted drug delivery systems due to its excellent biocompatibility, degradability, and multifunctionality for loading various therapeutic agents. PLGA nanoparticles (NPs) can achieve targeted delivery to tumor cells through specific surface modifications and stimulus-responsive release mechanisms, significantly enhancing drug accumulation efficiency at tumor sites while reducing toxic side effects on normal tissues. This review systematically summarizes the fundamental physicochemical properties of PLGA materials and recent advances in tumor-targeting strategies for PLGA NPs. It comprehensively elucidates research breakthroughs in PLGA-based delivery systems regarding stimulus-response mechanisms, passive targeting, active targeting, and tumor combination immunotherapy, while revealing the intrinsic logic of synergistic strategies for enhancing targeting efficiency. Finally, from the perspective of clinical translation and individualized oncology, this review conducts an in-depth assessment of the current challenges and looks forward to future research directions, aiming to provide forward-looking guidance for the development of precision nanomedicine.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China
Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100190, China
Key Laboratory of Bio-Based Material Science &Technology, Northeast Forestry University, Ministry of Education, Harbin 150040, China
The Ångström Laboratory, Nanotechnology and Functional Materials Division, Department of Engineering Sciences, Uppsala University, Box 534, SE-751 21 Uppsala, Sweden
Zhejiang International Science and Technology Cooperation Base for Biomass Resources Development and Utilization, Taizhou Key Laboratory of Biomedicine and Advanced Dosage Forms, School of Life Sciences, Taizhou University, Taizhou 318000, China
Funding
Beijing Natural Science Foundation · Industrial Key Science and Technology Program in Taizhou · GuoTai (Taizhou) Center of Technology Innovation for Veterinary Biologicals Program · National Natural Science Foundation of China
References (100+)
Show source-provided references
1. GBD 2023 Cancer Collaborators (2025). The Global, Regional, and National Burden of Cancer, 1990–2023, with Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023. Lancet, 406, 1565–1586.10.2139/ssrn.5533924 ↗
2. Research Progress on New Physical Therapies for Cancer (Review)10.3892/ol.2025.15059 ↗
3. Advances in Cancer Immunotherapy: Historical Perspectives, Current Developments, and Future Directions10.1186/s12943-025-02305-x ↗
4. Enhancing Therapeutic Performance of Personalized Cancer Vaccine via Delivery Vectors10.1016/j.addr.2021.113927 ↗
5. PLGA-Based Biodegradable Microspheres in Drug Delivery: Recent Advances in Research and Application10.1080/10717544.2021.1938756 ↗
6. Rocha, C.V., Gonçalves, V., Da Silva, M.C., Bañobre-López, M., and Gallo, J. (2022). PLGA-Based Composites for Various Biomedical Applications. Int. J. Mol. Sci., 23.10.3390/ijms23042034 ↗
7. Yang, J., Zeng, H., Luo, Y., Chen, Y., Wang, M., Wu, C., and Hu, P. (2024). Recent Applications of PLGA in Drug Delivery Systems. Polymers, 16.10.3390/polym16182606 ↗
8. Polymeric Nanoparticles for Drug Delivery10.1021/acs.chemrev.3c00705 ↗
9. A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century10.1002/adma.202308915 ↗
10. Engineering Precision Nanoparticles for Drug Delivery10.1038/s41573-020-0090-8 ↗
11. Zhang, D., Liu, L., Wang, J., Zhang, H., Zhang, Z., Xing, G., Wang, X., and Liu, M. (2022). Drug-Loaded PEG-PLGA Nanoparticles for Cancer Treatment. Front. Pharmacol., 13.10.3389/fphar.2022.990505 ↗
12. Rezvantalab, S., Drude, N.I., Moraveji, M.K., Güvener, N., Koons, E.K., Shi, Y., Lammers, T., and Kiessling, F. (2018). PLGA-Based Nanoparticles in Cancer Treatment. Front. Pharmacol., 9.10.3389/fphar.2018.01260 ↗
13. Biomedical Applications of PLGA Nanoparticles in Nanomedicine: Advances in Drug Delivery Systems and Cancer Therapy10.1080/17425247.2023.2223941 ↗
14. Nitric Oxide Nano-Reactor DNMF/PLGA Enables Tumor Vascular Microenvironment and Chemo-Hyperthermia Synergetic Therapy10.1186/s12951-024-02366-y ↗
15. Multifunctional Tumor-Targeted PLGA Nanoparticles Delivering Pt(IV)/siBIRC5 for US/MRI Imaging and Overcoming Ovarian Cancer Resistance10.1016/j.biomaterials.2020.120478 ↗
16. Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy
17. Kondiah, P. (2020). The Design of Poly(Lactide-Co-Glycolide) Nanocarriers for Medical Applications. Front. Bioeng. Biotechnol., 8.10.3389/fbioe.2020.00048 ↗
18. Biocompatibility, Biodegradation and Biomedical Applications of Poly(Lactic Acid)/Poly(Lactic-Co-Glycolic Acid) Micro and Nanoparticles10.1007/s40005-019-00439-x ↗
19. El-Hammadi, M.M., and Arias, J.L. (2022). Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials, 12.10.3390/nano12030354 ↗
20. Translating the Fabrication of Protein-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles from Bench to Scale-Independent Production Using Microfluidics10.1007/s13346-019-00699-y ↗
21. Reverse Engineering the 1-Month Lupron Depot®10.1208/s12248-018-0253-2 ↗
22. Minocycline-Loaded nHAP/PLGA Microspheres for Prevention of Injury-Related Corneal Angiogenesis10.1186/s12951-024-02317-7 ↗
23. White, C., and Schwendeman, S.P. (2026, January 05). Formulation and Characterization of Exenatide-Loaded PLGA Microspheres Prepared by Coacervation—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/41364402/.10.1007/s13346-025-02008-2 ↗
24. Hua, Y., Wang, Z., Wang, D., Lin, X., Liu, B., Zhang, H., Gao, J., and Zheng, A. (2021). Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol®. Molecules, 26.10.3390/molecules26051247 ↗
25. Poly(Lactide-Co-Glycolide) Nanoparticles for Peroral Delivery of Bioactives10.1016/j.cocis.2010.11.005 ↗
26. Development of a Fast and Precise Method for Simultaneous Quantification of the PLGA Monomers Lactic and Glycolic Acid by HPLC10.1016/j.jpha.2019.01.004 ↗
27. 3D PLGA Scaffolds Improve Differentiation and Function of Bone Marrow Mesenchymal Stem Cell–Derived Hepatocytes10.1089/scd.2009.0415 ↗
28. Efficacy and Safety of the Low-Temperature-Derived 3D Printed Biodegradable Mg-Containing Composite Porous Scaffold for Bone Defect Repair: A Prospective and Multi-Center Randomized Controlled Trial10.1016/j.biomaterials.2025.123751 ↗
29. Horvath, D., and Basler, M. (2023). PLGA Particles in Immunotherapy. Pharmaceutics, 15.10.3390/pharmaceutics15020615 ↗
30. Evaluation of Anti-Cancer Activity of PLGA Nanoparticles Containing Crocetin10.1080/21691401.2016.1198359 ↗
31. Noscapine Loaded PLGA Nanoparticles Prepared Using Oil-in-Water Emulsion Solvent Evaporation Method
32. Formulation, Characterization and Evaluation of Curcumin- Loaded PLGA- TPGS Nanoparticles for Liver Cancer Treatment10.2147/DDDT.S211748 ↗
33. Effect of the Emulsion Solvent Evaporation Technique Cosolvent Choice on the Loading Efficiency and Release Profile of Anti-CD47 from PLGA Nanospheres10.1016/j.xphs.2022.04.007 ↗
34. Development of Capecitabine-Encapsulated PEG-PLGA Nanoparticles Using Double Emulsion Solvent Evaporation for Sustained Drug Release10.1007/s12247-026-10494-1 ↗
35. Enhanced Nanoprecipitation Method for the Production of PLGA Nanoparticles for Oncology Applications10.1208/s12248-025-01096-9 ↗
36. Optimization of Parameters for Preparation of Docetaxel-Loaded PLGA Nanoparticles by Nanoprecipitation Method10.1007/s11596-013-1192-x ↗
37. Technical Aspects of Preparing PEG-PLGA Nanoparticles as Carrier for Chemotherapeutic agents by Nanoprecipitation Method10.1016/j.ijpharm.2017.09.054 ↗
38. Exploring a Mucoacting Spray-Dried Nanoparticle-in-Microparticle Inhalable Formulation for Targeted Pulmonary Delivery of Sorafenib in Lung Cancer Therapy10.1016/j.ijpharm.2025.126290 ↗
39. Preparation, Evaluation and Pharmacokinetic Studies of Spray Dried PLGA Polymeric Submicron Particles of Simvastatin for the Effective Treatment of Breast Cancer10.1016/j.molliq.2017.11.081 ↗
40. Production of 5-Fluorouracil-Loaded PLGA Nanoparticles with Toroidal Microfluidic System and Optimization of Process Variables by Design of Experiments10.1016/j.ijpharm.2024.124501 ↗
41. Effect of Organic Solvents on a Production of PLGA-Based Drug-Loaded Nanoparticles Using a Microfluidic Device10.1021/acsomega.2c03137 ↗
42. In Vitro and in Vivo Anti-Tumor Activities of Nanoparticles Based on Doxorubicin-PLGA Conjugates10.1016/S0168-3659(00)00280-7 ↗
43. Polyester-Based Nanoparticles for Nucleic Acid Delivery10.1016/j.msec.2018.07.027 ↗
44. Principles of Encapsulating Hydrophobic Drugs in PLA/PLGA Microparticles10.1016/j.ijpharm.2008.04.042 ↗
45. Recent Advances of PLGA Micro/Nanoparticles for the Delivery of Biomacromolecular Therapeutics10.1016/j.msec.2017.12.036 ↗
46. Lipid-Based Surface Engineering of PLGA Nanoparticles for Drug and Gene Delivery Applications10.1186/s40824-016-0081-3 ↗
47. Efficient Co-Loading of Paclitaxel and Gefitinib in PLGA Nanoparticles: Use of Design of Experiments (DoE) Approach for Enhanced Efficacy Against MCF-7/MCF-7ADR Cells10.1002/pat.70424 ↗
48. Lyophilizable Polymer-Lipid Hybrid Nanoparticles with High Paclitaxel Loading10.1021/acsanm.4c03107 ↗
49. Raposo, C.D., Costa, R., Petrova, K.T., Brito, C., Scotti, M.T., and Cardoso, M.M. (2020). Development of Novel Galactosylated PLGA Nanoparticles for Hepatocyte Targeting Using Molecular Modelling. Polymers, 12.10.3390/polym12010094 ↗
50. Vallorz, E.L., Encinas-Basurto, D., Schnellmann, R.G., and Mansour, H.M. (2022). Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles. Pharmaceutics, 14.10.3390/pharmaceutics14030638 ↗
51. Liu, G., and McEnnis, K. (2022). Glass Transition Temperature of PLGA Particles and the Influence on Drug Delivery Applications. Polymers, 14.10.3390/polym14050993 ↗
52. Controlled Release and Targeted Drug Delivery with Poly(Lactic-Co-Glycolic Acid) Nanoparticles: Reviewing Two Decades of Research10.1007/s40005-022-00584-w ↗
53. Smart Polymer Microspheres: Preparation, Microstructures, Stimuli-Responsive Properties, and Applications10.1021/acsnano.5c00998 ↗
54. Dual-Stimuli-Responsive Microparticles10.1021/acsami.5b01592 ↗
55. Advanced Application of Stimuli-Responsive Drug Delivery System for Inflammatory Arthritis Treatment10.1016/j.mtbio.2022.100223 ↗
56. Nanocarrier Strategies for Deep Tumour Penetration10.1039/D5LP00154D ↗
57. pH-Responsive High Stability Polymeric Nanoparticles for Targeted Delivery of Anticancer Therapeutics10.1038/s42003-020-0817-4 ↗
58. Insights in the Rheological Properties of PLGA-PEG-PLGA Aqueous Dispersions: Structural Properties and Temperature-Dependent Behaviour10.1016/j.polymer.2020.123216 ↗
59. Injectable Biodegradable Temperature-Responsive PLGA-PEG-PLGA Copolymers: Synthesis and Effect of Copolymer Composition on the Drug Release from the Copolymer-Based Hydrogels10.1016/j.ijpharm.2005.01.017 ↗
60. TCPP-Isoliensinine Nanoparticles for Mild-Temperature Photothermal Therapy10.2147/IJN.S317462 ↗
61. Magnetic Systems for Cancer Immunotherapy10.1016/j.apsb.2021.03.023 ↗
62. Chen, H.-A., Ma, Y.-H., Hsu, T.-Y., and Chen, J.-P. (2020). Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy. Int. J. Mol. Sci., 21.10.3390/ijms21082690 ↗
63. The Combined Magnetic Field and Iron Oxide-PLGA Composite Particles: Effective Protein Antigen Delivery and Immune Stimulation in Dendritic Cells10.1016/j.jcis.2018.03.008 ↗
64. Enzyme-Responsive Nanomaterials for Controlled Drug Delivery10.1039/C4NR04249B ↗
65. Cathepsin B-Responsive Dendronized-Hyaluronic Acid Nanomedicine for Simultaneous Cancer Theranostics10.1002/mog2.70035 ↗
66. Subhan, M.A., Parveen, F., Filipczak, N., Yalamarty, S.S.K., and Torchilin, V.P. (2023). Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis. J. Pers. Med., 13, Available online: https://www.mdpi.com/2075-4426/13/3/389.10.3390/jpm13030389 ↗
67. PLGA Nanoparticles Containing Various Anticancer Agents and Tumour Delivery by EPR Effect10.1016/j.addr.2010.10.008 ↗
68. Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review10.1016/S0168-3659(99)00248-5 ↗
69. Toward a Full Understanding of the EPR Effect in Primary and Metastatic Tumors as Well as Issues Related to Its Heterogeneity10.1016/j.addr.2015.01.002 ↗
70. Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery10.2174/1381612824666180730161721 ↗
71. Morshedi, B., Esfandyari-Manesh, M., Ghahremani, M.H., Fatahi, Y., and Dinarvand, R. (2025). Localized Co-Delivery of in-Situ Hydrogel Containing Ibrutinib-PLGA-PEG-Folate Nanoparticle and Octreotide Microsphere to Glioblastoma. Drug Deliv. Transl. Res., online ahead of print.10.1007/s13346-025-01999-2 ↗
72. Effects of Particle Size and Surface Charge on Cellular Uptake and Biodistribution of Polymeric Nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
73. Sharifi, M., Cho, W.C., Ansariesfahani, A., Tarharoudi, R., Malekisarvar, H., Sari, S., Bloukh, S.H., Edis, Z., Amin, M., and Gleghorn, J.P. (2022). An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment. Cancers, 14.10.3390/cancers14122868 ↗
74. Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation10.1021/acsnano.2c08451 ↗
75. Advances in PLGA-Based Polymeric Nanocarriers for Colorectal Cancer Therapy: Overcoming Chemoresistance through Controlled Delivery Strategies10.1186/s12943-025-02435-2 ↗
76. The Mechanisms of Nanoparticle Delivery to Solid Tumours10.1038/s44222-024-00154-9 ↗
77. Pharmacokinetics and Tumor Delivery of Nanoparticles10.1016/j.jddst.2023.104404 ↗
78. Ejigah, V., Owoseni, O., Bataille-Backer, P., Ogundipe, O.D., Fisusi, F.A., and Adesina, S.K. (2022). Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect. Polymers, 14.10.3390/polym14132601 ↗
79. Advances in Targeted Therapy for Tumor with Nanocarriers: A Review10.1016/j.mtbio.2025.101583 ↗
80. Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma10.1016/j.mtbio.2023.100895 ↗
81. An Overview of Active and Passive Targeting Strategies to Improve the Nanocarriers Efficiency to Tumour Sites10.1111/jphp.13098 ↗
82. Khan, I., Gothwal, A., Sharma, A.K., Kesharwani, P., Gupta, L., Iyer, A.K., and Gupta, U. (2026, January 10). PLGA Nanoparticles and Their Versatile Role in Anticancer Drug Delivery—Critical ReviewsTM in Therapeutic Drug Carrier Systems, Volume 33, 2016, Issue 2—Begell House Digital Library. Available online: https://www.dl.begellhouse.com/journals/3667c4ae6e8fd136,3e868ea50400cfbb,356e2ffb0a73d4f1.html.
83. Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy10.1021/bm5003009 ↗
84. Cytotoxicity of Targeted PLGA Nanoparticles: A Systematic Review10.1039/D1RA00074H ↗
85. PLGA-Based Nanoparticles as Cancer Drug Delivery Systems10.7314/APJCP.2014.15.2.517 ↗
86. The Application of Nanoparticles in Cancer Immunotherapy: Targeting Tumor Microenvironment
87. Top-Down and Middle-Down Mass Spectrometry of Antibodies10.1016/j.mcpro.2025.100989 ↗
88. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations10.2174/0929867324666170817152554 ↗
89. Antibody and Antibody Fragments for Cancer Immunotherapy10.1016/j.jconrel.2020.08.021 ↗
90. New Technologies Bloom Together for Bettering Cancer Drug Conjugates10.1124/pharmrev.121.000499 ↗
91. Wang, T., Liu, L., and Voglmeir, J. (2026, January 11). mAbs N-Glycosylation: Implications for Biotechnology and Analytics-Web of Science Core Collection. Available online: https://webofscience.clarivate.cn/wos/woscc/full-record/WOS:000804197400007.
92. Carbon Dot-Based Fluorescent Antibody Nanoprobes as Brain Tumour Glioblastoma Diagnostics10.1039/D2NA00060A ↗
93. Napabucasin Deactivates STAT3 and Promotes Mitoxantrone-Mediated cGAS-STING Activation for Hepatocellular Carcinoma Chemo-Immunotherapy10.1016/j.biomaterials.2024.122766 ↗
94. Engineering Anti-c-MET scFv-Conjugated PLGA Nanoparticles for Precision Verteporfin Delivery in Lung Cancer Cells: A Formulation Study10.1016/j.ijpharm.2025.126004 ↗
95. PEGylated Antibodies and Antibody Fragments for Improved Therapy: A Review10.1016/S0169-409X(02)00026-1 ↗
96. Castro, A., Pittini, Á., Berois, N., Faccio, R., Miranda, P., Mombrú, Á.W., Osinaga, E., and Pardo, H. (2026, January 11). Development, Characterization, and Evaluation of Chi-Tn mAb-Functionalize1d DOTAP-PLGA Hybrid Nanoparticles Loaded with Docetaxel for Lung Cancer Therapy-Web of Science Core Collection. Available online: https://webofscience.clarivate.cn/wos/woscc/full-record/WOS:001429759600001.
97. Advance in Peptide-Based Drug Development: Delivery Platforms, Therapeutics and Vaccines10.1038/s41392-024-02107-5 ↗
98. Cooperative Nutrient Scavenging Is an Evolutionary Advantage in Cancer10.1038/s41586-025-08588-w ↗
99. Nanobodies Targeting the Tumor Microenvironment and Their Formulation as Nanomedicines10.1186/s12943-025-02270-5 ↗
100. Multivalent Assembly of Nucleolin-Targeted F3 Peptide Potentiates TRAIL’s Tumor Penetration and Antitumor Effects10.1016/j.jconrel.2025.113835 ↗